French plan company payback on hepatitis C drug spending
This article was originally published in Scrip
Executive Summary
The French authorities have some plans up their sleeve to curb spending on medicines, including an industry payback mechanism to regulate state spending on the new hepatitis C drugs such as Gilead's Sovaldi (sofosbuvir). Also on the cards are price cuts (savings of up to €550m) and greater use of generics and biosimilars (€465m).